Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Guselkumab - Janssen Biotech

Drug Profile

Guselkumab - Janssen Biotech

Alternative Names: CNTO-1959; TREMFYA; TREMFYA ONE-PRESS

Latest Information Update: 27 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer Janssen Biotech; Janssen Research & Development; Janssen-Cilag; MorphoSys; Taiho Pharmaceutical
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythrodermic psoriasis; Palmoplantar pustulosis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Phase III Psoriasis
  • Phase II/III Crohn's disease; Ulcerative colitis
  • Phase II Hidradenitis suppurativa; Rheumatoid arthritis
  • Phase I Familial adenomatous polyposis

Most Recent Events

  • 29 Nov 2019 Phase-I clinical trials in Plaque psoriasis (In volunteers) in China (IV,Infusion) (NCT04030533)
  • 29 Nov 2019 Phase-I clinical trials in Plaque psoriasis (In volunteers) in China (SC,Injection) (NCT04030533)
  • 26 Nov 2019 Janssen Research & Development suspends the phase-II/III QUASAR trial in Ulcerative colitis (Treatment-experienced) in Belgium, Hungary, USA, United Kingdom (NCT04033445) (EudraCT2018-004002-25)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top